ClinicalTrials.gg
CompletedNCT06683937COV-IDUpdated Oct 6, 2026

Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19.

An observational study in Immunocompromised Patients and SARS-CoV-2 Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Updated Oct 6, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
327
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Assistance Publique - Hôpitaux de Paris.

Enrollment
31st of 56
327 · median 489
Started
2024
with 1 other
Observational
56 of 115
5 open now
Registered
113th of 115
by date

Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, this one is the 31st largest by enrollment of the 56 observational ones that give a count, is one of 2 that started in 2024, is one of 56 observational ones, and was the 113th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months worldwide. However, these infections remain a major public health problem in severely immunocompromised patients, who have decreased vaccine efficacy and are at higher risk of persistent SARS-CoV-2 viral shedding, relapses, secondary invasive fungal infection, intensive care unit hospitalization, and death than non-immunocompromised patients.

The research concerns adult patients at very high risk of severe SARS-CoV-2 disease, suffering from SARS-CoV-2 having resulted in hospitalization in a center participating in the study in France between June 1, 2023 and April 1, 2024 and having received mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir in order to carry out an evaluation of direct antiviral treatments against SARS-CoV-2 in these immunocompromised patients suffering from Covid-19.

The study consists of collecting patient care data from the medical record. Patients will be identified by practitioners at each participating French center.

Read the detailed description

Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months worldwide. However, these infections remain a major public health problem in severely immunocompromised patients, who have decreased vaccine efficacy and are at higher risk of persistent SARS-CoV-2 viral shedding, relapses, secondary invasive fungal infection, intensive care unit hospitalization, and death than non-immunocompromised patients.

The research concerns adult patients at very high risk of severe SARS-CoV-2 disease, suffering from SARS-CoV-2 having resulted in hospitalization in a center participating in the study in France between June 1, 2023 and April 1, 2024 and having received mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir in order to carry out an evaluation of direct antiviral treatments against SARS-CoV-2 in these immunocompromised patients suffering from Covid-19.

Identifying an effective anti-SARS-CoV-2 therapeutic strategy is a real challenge in severely immunocompromised patients because clinicians are faced with chronic carriage and serious complications in these patients, as well as drug interactions with immunosuppressive treatments, the emergence of resistance and the absence of recommendations.

The data currently available in the literature remain heterogeneous and sometimes without sufficient level of evidence. However, some teams have reported in this population the efficacy of repeated or prolonged treatment with nirmatrelvir/ritonavir or even multitherapies combining several antiviral treatments and/or combinations of monoclonal antibodies on persistent carriage of the virus. Thus, some centers recommend prolonged antiviral treatments combining 5 to 10 days of remdesivir with 10 days of nirmatrelvir/ritonavir.

Nirmatrelvir/ritonavir and remdesivir are the currently available antiviral therapies that are still effective against circulating Omicron virus subvariants. It therefore seems important to have more data on their efficacy in monotherapy, dual therapy, or in the case of prolonged treatment.

The study consists of collecting patient care data from the medical record. Patients will be identified by practitioners at each participating French center.

03

Conditions studied

  • Immunocompromised Patients
  • SARS-CoV-2 Disease

Browse trials for

Keywords

  • Immunocompromised patients
  • SARS-CoV-2 disease
  • Mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients at very high risk of severe SARS-CoV-2 disease, hospitalized for SARS-CoV-2 infection from June 2023 to April 2024 in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with SARS-CoV-2 in France, treated in a center participating in the study
  • Symptomatic patients for Covid-19 who have received mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir
  • SARS-CoV-2 positive by PCR on nasopharyngeal swab, ECBC or bronchoalveolar fluid
  • Hospitalization in a ward or day hospital for SARS-CoV-2 infection
  • Patients at very high risk of severe form of SARS-CoV-2

    • Aggressive lymphomas (all types)
    • Acute lymphocytic leukemia
    • Acute myeloid leukemia
    • Acute promyelocytic leukemia
    • T-cell prolymphocytic leukemia
    • Primary lymphoma of the central nervous system
    • Stem cell transplant
    • Light chain amyloidosis
    • Chronic lymphocytic leukemia
    • Multiple myeloma
    • Hematopoietic stem cell transplant
    • Solid organ transplant
    • Being on the waiting list for an organ transplant
    • Primary immunodeficiency;
    • patients with CD4 \<200/mm3 or with a detectable viral load
    • Lymphopenia \<200/mm3
    • Neutropenia \<1000/mm3 for > 1 week
    • Patients receiving long-term treatment (period of at least 3 months during treatment during infection) with:
  • anti-CD20 antibodies
  • anti-JAK
  • BTK inhibitors
  • azathioprine
  • cyclophosphamide
  • methotrexate
  • mycophenolate mofetil
  • CAR-T cell gene therapy
  • bi-phenotypic therapeutic antibodies
  • tacrolimus
  • sirolimus
  • long-term (prednisone equivalent dose >5mg for 3 months)

Exclusion criteria

Exclusion Criteria:

  • Opposition formulated (following receipt of the study information note)
  • Patients who received convalescent plasma as treatment for SARS-CoV-2 infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
327 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients

    Adult patients at very high risk of severe SARS-CoV-2 disease, hospitalized for SARS-CoV-2 infection from June 2023 to April 2024.

    Other: Collection of data from the patient's medical file

Interventions

  • OtherCollection of data from the patient's medical file

    Collection of data from the patient's medical file

06

What researchers measure

Primary outcomes

  1. Clinical evolution of immunocompromised patients receiving remdesivir and/or nirmatrelvir/ritonavir as curative treatment for COVID-19

    Evolution of the patient's modified (suitable for immunocompromised patients) Ordinal Scale for Clinical Improvement (OSCI) of the World Health Organization (WHO) (score from 0 - non infected patient to 8 - deceased patient) from the initiation of treatment to 30 days (+7 days) following the first line of therapy.

    Time frame: 37 days

Secondary outcomes

  1. Mortality at 30 days of diagnosis

    Mortality at 30 days of diagnosis

    Time frame: 30 days

  2. Tolerance of antiviral treatments against SARS-CoV-2

    Rate of serious side effects within 6 months (grade 3 and 4 on adverse event scale).

    Time frame: 6 months

  3. Evaluate virological evolution

    Decrease or negativity of PCR between D2 and D30 following the first line of anti-SARS-CoV-2 therapy, then at D60.

    Time frame: 60 days

  4. Evaluate radiological evolution

    Reduction or disappearance of radiological lung lesions after the first line of therapy.

    Time frame: 90 days

  5. Clinical relapse at discharge from hospital, at D30 and D60

    Modified (suitable for immunocompromised patients ) OSCI score (Ordinal Scale for Clinical Improvement of the World Health Organization, score from 0 - non infected patient to 8 - deceased patient)at hospital discharge, D30 and D60. Maximum modified OSCI score between H48 and D30.

    Time frame: 90 days

  6. Identified factors associated with favorable evolution

    Description of clinical evolution adjusted for age and other variables of interest.

    Time frame: 90 days

  7. Infectious complications and secondary non-infectious complications

    Incidence of infectious complications (aspergillosis and bacterial infections) and secondary non-infectious complications. Collection of the following elements: * Use of a second line of therapy (antivirals and plasma therapy) specifying the time after the first line * occurrence of complications during the initial hospitalization after the first line of therapy: pulmonary embolism, hospitalization in the Intensive Care Unit, probable or proven invasive fungal infections (aspergillosis, mucormycosis with initiation of antifungal treatment), bacterial infection (antibiotics initiated) * persistence of viral carriage (\> 3 weeks and \>8 weeks)

    Time frame: 90 days

07

Study locations

18 sites
  • CHU Angers
    Angers, 49000, France
  • Hôpital Pasteur, Colmar
    Colmar, 68000, France
  • Hôpital Henri Mondor
    Créteil, 94000, France
  • CHD Vendée (La Roche sur Yon)
    La Roche-sur-Yon, 85000, France
  • Hôpital Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • CHRU Lille
    Lille, 59000, France
  • CHU Nord Marseille
    Marseille, 13000, France
  • CHU Nantes
    Nantes, 44000, France
  • CHU Nîmes Caremeau
    Nîmes, 30000, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Hôpital Saint Antoine
    Paris, 75012, France
  • Hôpital Necker-Enfants Malades
    Paris, 75015, France
  • Hôpital Bichat
    Paris, 75018, France
  • CH Périgueux
    Périgueux, 24000, France
  • CHU Poitiers
    Poitiers, 86000, France
  • CHU Reims
    Reims, 51100, France
  • CHU Sud Réunion
    Saint-Pierre, 97410, France
  • CHU Toulouse
    Toulouse, 31000, France
08

References and documents

Publications

  • Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, Haniffa R, Reveiz L, Ford N, Doherty M, Diaz J. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul;9(7):e486-e495. doi: 10.1016/S2352-3018(22)00097-2. Epub 2022 May 10. PubMed 35561704 ↗
  • DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006. Epub 2022 Sep 13. PubMed 36182669 ↗
  • MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022 Jul;4(7):e490-e506. doi: 10.1016/S2665-9913(22)00098-4. Epub 2022 Jun 9. PubMed 35698725 ↗
  • Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, Bell S, Carty L, Evans K, Graham S, Justo N, Moss P, Venkatesan S, Yokota R, Ferreira C, McNulty R, Taylor S, Quint JK. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023 Oct 13;35:100747. doi: 10.1016/j.lanepe.2023.100747. eCollection 2023 Dec. PubMed 38115964 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in Jul 2025, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Dec 2025 → Dec 2024, primary completion Jun 2026 → Jul 2025 and completion Jun 2026 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 12, 2024
StartActual
Dec 14, 2024was Dec 2025
Primary completionActual
Jul 18, 2025was Jun 2026
CompletionActual
Jul 18, 2025was Jun 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 6, 2026
Sites
3 sites added, 1 site removed
Show 3 added (3 France)
  • Hôpital Henri Mondor · Créteil, France
  • Hôpital Bicêtre · Le Kremlin-Bicêtre, France
  • Hôpital Saint Antoine · Paris, France
Show 1 removed
  • CHU Caen · Caen, France
Oct 6, 2026
Start date
Dec 1, 2025→Dec 14, 2024 (actual)
Oct 6, 2026
Primary completion
Jun 1, 2026→Jul 18, 2025 (actual)
Oct 6, 2026
Study completion
Jun 1, 2026→Jul 18, 2025 (actual)
Oct 6, 2026
Enrollment
300 (estimated)→327 (actual)
Oct 6, 2026
Title
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Completed
    3 sites added, 1 site removed
    Show 3 added (3 France)
    • Hôpital Henri Mondor · Créteil, France
    • Hôpital Bicêtre · Le Kremlin-Bicêtre, France
    • Hôpital Saint Antoine · Paris, France
    Show 1 removed
    • CHU Caen · Caen, France
    Start date Dec 1, 2025→Dec 14, 2024 (now actual)
    Primary completion Jun 1, 2026→Jul 18, 2025 (now actual)
    Study completion Jun 1, 2026→Jul 18, 2025 (now actual)
    Enrollment 300 (estimated)→327 (actual)
    Title Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06683937
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Dec 14, 2024
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Last update
Oct 6, 2026

Study contacts

Cléa Melenotte, M.D.
principal investigator · Assistance Publique - Hôpitaux de Paris
Clémentine de La Porte, M.D.
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion